AI-Generated Filing Summaries

Thermon Group Holdings, Inc. (NYSE: THR) posted an updated investor presentation entitled “THR Investor Presentation (Mar 2026)” to its investor relations website at https://ir.thermon.com on March 23, 2026, pursuant to Item 7.01 Regulation FD Disclosure. This furnishing provides investors access to the updated presentation materials.

Xilio Therapeutics announced fourth quarter and full year 2025 financial results on March 23, 2026, reporting collaboration and license revenue of $13.7 million for Q4 and net income of $10.4 million, alongside a cash position of $137.5 million as of December 31, 2025. The company provided pipeline updates on XTX501 and masked T cell engagers, with cash runway extended through the end of 2027.

InMed Pharmaceuticals Inc. announced positive preclinical data from human brain organoid neuroinflammation models supporting the INM-901 Alzheimer's disease program, showing dose-dependent reduction of pro-inflammatory markers IL-6 and IL-8. The results translate prior animal model findings to human-relevant systems, de-risking the program ahead of a planned pre-IND meeting in Q3/2026 and Phase 1 trial in 2027.

Cabaletta Bio, Inc. announced financial results for the fourth quarter and full year ended December 31, 2025, with research and development expenses of $36.2 million and $142.7 million, respectively, and cash, cash equivalents and short-term investments of $133.6 million as of December 31, 2025. The company provided business updates on rese-cel clinical programs, including myositis registrational cohort enrollment and upcoming data presentations in 1H26.

Cabaletta Bio, Inc. (CABA), a clinical-stage biotechnology company, reported a net loss of $167.9 million for FY 2025, ending December 31, 2025, compared to $115.9 million in FY 2024, driven by higher operating expenses of $172.2 million versus prior year levels. Research and development expenses rose to $142.7 million from increased clinical trial activities across RESET programs for rese-cel in autoimmune diseases like SLE, myositis, SSc, gMG, and PV. General and administrative expenses were $29.6 million. No revenue was generated, reflecting pre-commercial status. Balance sheet shows total assets of $165.1 million, with cash and equivalents at $83.0 million and short-term investments at $50.6M, down due to $131.1 million net cash used in operations and $50.3 million in investing activities, offset by $100.3 million from financing including $93.6 million from common stock issuance. Stockholders’ equity stood at $112.1 million. Net loss per share was -$2 basic and diluted, consistent with prior year. Cash position supports operations into Q4 2026, funding Phase 1/2 trial completions and data readouts, positioning for potential BLA submissions by 2027 amid ongoing registrational cohorts.

State Street Corporation’s Board of Directors elected Susan Gordon as an independent director on March 19, 2026, and appointed her to the Examining and Audit Committee and Technology and Operations Committee. Ms. Gordon will receive a pro rata share of the 2025-2026 $110,000 annual retainer and $235,000 common stock retainer, with the stock award based on the NYSE closing price on the election date.

State Street Corporation’s Board of Directors elected Susan Gordon as an independent director on March 19, 2026, and appointed her to the Examining and Audit Committee and Technology and Operations Committee. Ms. Gordon will receive a pro rata share of the 2025-2026 $110,000 annual retainer and $235,000 common stock retainer, with the stock award based on the NYSE closing price on the election date.

Xilio Therapeutics, Inc., a clinical-stage biotech firm, reported total revenue of $43.8 million for FY 2025, a significant increase from $6.3 million in FY 2024, driven by collaboration and license revenue from agreements with AbbVie ($20.1 million) and Gilead ($23.6 million), including milestones. This marked a YoY revenue growth of approximately 591%. Operating expenses rose to $85.7 million from $66.9 million, reflecting higher R&D ($56.0 million vs $41.2 million) due to clinical advancements in vilastobart, efarindodekin alfa, and XTX501, and G&A ($29.7 million vs $24.8 million). Loss from operations narrowed to -$42.0 million from -$60.6 million. Net loss improved to -$35.0 million from -$58.2 million, aided by a $5.8 million gain from changes in common stock warrant liabilities and $1.1 million other income. Basic and diluted EPS was -$4.00 per share on 8.4 million weighted average shares. Balance sheet strengthened with cash and equivalents at $137.5 million (up from $55.3 million), total assets $154.7 million, and stockholders' equity $35.3 million. Net cash used in operations was -$5.0 million vs -$18.4 million YoY, with financing providing $87.8 million mainly from warrant offerings. Management states cash sufficient through end-2027, excluding milestones, supporting pipeline advancement without near-term dilution needs.

Two Harbors Investment Corp. announced that its ad hoc committee determined CrossCountry Mortgage, LLC's unsolicited proposal to acquire all common stock for $10.70 per share in cash constitutes a 'Company Superior Proposal' under the December 17, 2025 merger agreement with UWMC, with notice delivered March 21, 2026, starting a match right period ending March 25, 2026. The Company also received an additional third-party proposal at $10.75 per share and postponed its Special Meeting to April 7, 2026.

Two Harbors Investment Corp. announced that its ad hoc committee determined CrossCountry Mortgage, LLC's unsolicited proposal to acquire all common stock for $10.70 per share in cash constitutes a 'Company Superior Proposal' under the December 17, 2025 merger agreement with UWMC, with notice delivered March 21, 2026, starting a match right period ending March 25, 2026. The Company also received an additional third-party proposal at $10.75 per share and postponed its Special Meeting to April 7, 2026.

Two Harbors Investment Corp. announced that its ad hoc committee determined CrossCountry Mortgage, LLC's unsolicited proposal to acquire all common stock for $10.70 per share in cash constitutes a 'Company Superior Proposal' under the December 17, 2025 merger agreement with UWMC, with notice delivered March 21, 2026, starting a match right period ending March 25, 2026. The Company also received an additional third-party proposal at $10.75 per share and postponed its Special Meeting to April 7, 2026.

Two Harbors Investment Corp. announced that its ad hoc committee determined CrossCountry Mortgage, LLC's unsolicited proposal to acquire all common stock for $10.70 per share in cash constitutes a 'Company Superior Proposal' under the December 17, 2025 merger agreement with UWMC, with notice delivered March 21, 2026, starting a match right period ending March 25, 2026. The Company also received an additional third-party proposal at $10.75 per share and postponed its Special Meeting to April 7, 2026.

GSK plc purchased 560,000 ordinary shares of 31¼ pence each on 20 March 2026 through BNP Paribas SA at prices from 1,940.50p to 1,967.50p (VWAP 1,953.58p), to be held as treasury shares under its existing buyback programme announced on 17 February 2026. Post-purchase, treasury shares total 253,222,615 (6.23% of voting rights) with 4,062,953,663 voting rights.

GSK plc purchased 560,000 ordinary shares of 31¼ pence each on 20 March 2026 through BNP Paribas SA at prices from 1,940.50p to 1,967.50p (VWAP 1,953.58p), to be held as treasury shares under its existing buyback programme announced on 17 February 2026. Post-purchase, treasury shares total 253,222,615 (6.23% of voting rights) with 4,062,953,663 voting rights.

Solo Brands, Inc. reported FY 2025 net sales of $316.6 million, a 30.3% decline from $454.6 million in 2024, primarily due to lower DTC and retail sales in the Solo Stove segment, partially offset by Chubbies growth. Gross profit decreased to $188.1 million from $260.3 million, but gross margin improved to 59.4% from 57.3%, reflecting cost management amid lower volumes. Operating loss narrowed to $113.5 million from $174.6 million, driven by reduced restructuring charges ($93.5 million vs. higher prior) and lower SG&A ($176.2 million). Net loss attributable to Solo Brands was $101.3 million, improved from $113.4 million, with EPS of -$64 vs. -$77.66. Cash from operations was -$46.6 million, with free cash flow at -$58.6 million after $12.0 million capex. Balance sheet shows total assets down to $360.3 million, debt at $242.1 million net, equity $51.4 million. Key challenges include tariffs, impairments, and going concern doubts, mitigated by refinancing and cost cuts. Forward, focus on supply chain diversification, DTC enhancements, and Chubbies expansion amid seasonality shifts.

On March 17, 2026, Jennifer Jarrett notified Arcus Biosciences, Inc. of her resignation as Chief Operating Officer, effective March 30, 2026, not due to any disagreement with the Company. The Company entered a separation agreement providing for her periodic advisory services through June 30, 2026, extension of post-termination vested option exercise period to 12 months, and a standard release of claims.

Mesoblast Limited filed Exhibit 99.1 containing four Appendix 3Y Change of Director’s Interest Notices disclosing issuances of options to directors Dr Silviu Itescu (2,025,600 options on 17 March 2026), Dr Eric Rose (820,000 options on 18 March 2026), Gregory George (200,000 options on 16 March 2026), and Lyn Cobley (200,000 options on 18 March 2026), approved at the 2025 AGM for nil consideration.

Mesoblast Limited filed Exhibit 99.1 containing four Appendix 3Y Change of Director’s Interest Notices disclosing issuances of options to directors Dr Silviu Itescu (2,025,600 options on 17 March 2026), Dr Eric Rose (820,000 options on 18 March 2026), Gregory George (200,000 options on 16 March 2026), and Lyn Cobley (200,000 options on 18 March 2026), approved at the 2025 AGM for nil consideration.

Gyre Pharmaceuticals Co., Ltd., Gyre Therapeutics, Inc.’s majority indirectly owned subsidiary, submitted a New Drug Application to the Center for Drug Evaluation of China’s National Medical Products Administration for F351 (Hydronidone), its lead product candidate, for chronic hepatitis B-induced liver fibrosis on March 22, 2026. The submission is subject to initial verification, with potential supplementary materials and subsequent issuance of an acceptance number before technical review.

Strategy Inc announced an ATM program update, with sales of 509,111 shares of MSTR Class A Common Stock from March 16 to 22, 2026, generating $76.5 million in net proceeds used to acquire 1,031 BTC at an average price of $74,326. As of March 22, 2026, total BTC holdings are 762,099 BTC with an aggregate purchase price of $57.69 billion.

Strategy Inc announced an ATM program update, with sales of 509,111 shares of MSTR Class A Common Stock from March 16 to 22, 2026, generating $76.5 million in net proceeds used to acquire 1,031 BTC at an average price of $74,326. As of March 22, 2026, total BTC holdings are 762,099 BTC with an aggregate purchase price of $57.69 billion.

Strategy Inc announced an ATM program update, with sales of 509,111 shares of MSTR Class A Common Stock from March 16 to 22, 2026, generating $76.5 million in net proceeds used to acquire 1,031 BTC at an average price of $74,326. As of March 22, 2026, total BTC holdings are 762,099 BTC with an aggregate purchase price of $57.69 billion.

Strategy Inc announced an ATM program update, with sales of 509,111 shares of MSTR Class A Common Stock from March 16 to 22, 2026, generating $76.5 million in net proceeds used to acquire 1,031 BTC at an average price of $74,326. As of March 22, 2026, total BTC holdings are 762,099 BTC with an aggregate purchase price of $57.69 billion.

Strategy Inc announced an ATM program update, with sales of 509,111 shares of MSTR Class A Common Stock from March 16 to 22, 2026, generating $76.5 million in net proceeds used to acquire 1,031 BTC at an average price of $74,326. As of March 22, 2026, total BTC holdings are 762,099 BTC with an aggregate purchase price of $57.69 billion.

GSK plc announced that risvutatug rezetecan (Ris-Rez), a B7-H3-targeted antibody-drug conjugate, received Orphan Drug Designation from Japan's Ministry of Health, Labour and Welfare for small-cell lung cancer (SCLC). The designation, supported by phase I ARTEMIS-001 trial data showing durable responses in extensive-stage SCLC, marks the sixth global regulatory designation for Ris-Rez.

GSK plc announced that risvutatug rezetecan (Ris-Rez), a B7-H3-targeted antibody-drug conjugate, received Orphan Drug Designation from Japan's Ministry of Health, Labour and Welfare for small-cell lung cancer (SCLC). The designation, supported by phase I ARTEMIS-001 trial data showing durable responses in extensive-stage SCLC, marks the sixth global regulatory designation for Ris-Rez.

Fusion Fuel Green PLC appointed James Passin to its Board of Directors under a Director Agreement dated March 17, 2026, providing an annual fee of €50,000 paid quarterly in advance plus expense reimbursement and indemnification. The appointment supports the company's planned acquisition of a controlling interest in Royal Uranium Inc. to pursue a uranium royalty strategy, as detailed in Exhibit 99.1 press release dated March 23, 2026.

Newbridge Acquisition Limited Unit (NBRGU), a blank check company, reported a net loss of $221K for FY2025 ended December 31, 2025, up from $141K in FY2024, driven solely by formation and operating costs with no revenue generated. Total assets stood at $4.8M, comprising $1.8M cash, $2.7M cash and marketable securities held in trust, and $295K deferred offering costs. Liabilities totaled $5.4M, primarily from a related party promissory note, resulting in a shareholders' deficit of $595K and accumulated deficit of $620K. Cash flows reflected $221K used in operations, $2.7M used in investing for trust deposit, and $4.7M provided by financing, yielding a $1.8M net increase in cash. Basic and diluted net loss per ordinary share was $0.00 on 1.6M weighted average shares. Post-period, on February 2, 2026, the company completed its IPO of 5.75M units at $10.00, raising $57.5M gross proceeds deposited into trust, positioning it to pursue an initial business combination within 15-21 months. Management highlights going concern doubts due to working capital deficit of $3.6M and ongoing public company costs, reliant on sponsor loans and potential business combination.

Byrna Technologies Inc. furnished an updated investor presentation dated March 23, 2026, attached as Exhibit 99.1 under Item 7.01 Regulation FD Disclosure, for potential use in investor presentations. This information, including the exhibit, is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934 or subject to related liabilities.

NN, Inc. furnished an updated investor presentation under Item 7.01 Regulation FD Disclosure for the 38th Annual ROTH Conference on March 23-24, 2026, providing 2026 guidance of net sales $445-465 million and adjusted EBITDA $50-60 million. The presentation highlights new business wins of $70-80 million in 2026 and an ongoing strategic review of financial and strategic options.